Stock Track | Phathom Pharmaceuticals Soars 5.79% Pre-market on Strong Q3 Earnings and Analyst Upgrade

Stock Track

Oct 31

Phathom Pharmaceuticals (PHAT) saw its stock surge 5.79% in pre-market trading on Friday, following the release of its third-quarter earnings report for 2025 and a positive analyst update. The biopharmaceutical company's shares responded favorably to what appears to be strong financial results and an improved outlook from Wall Street.

The company's Q3 earnings release, which came out late Thursday, seems to have impressed investors. While specific details were not provided, the report likely showcased significant growth and potentially better-than-expected performance for Phathom Pharmaceuticals. This positive financial data appears to be a key driver behind the stock's pre-market rally.

Adding to the bullish sentiment, H.C. Wainwright raised its target price for Phathom Pharmaceuticals from $20 to $26, representing a substantial increase in their valuation of the company. Furthermore, HC Wainwright & Co. maintained its "Buy" rating on the stock, reinforcing confidence in Phathom's future prospects. These analyst actions suggest that Wall Street sees potential for further growth and value creation in Phathom Pharmaceuticals, likely contributing to the stock's early morning surge.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1128129861"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1128129861\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1128129861?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 21:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128129861","market":"hk","top_or_hot":-1,"title":"Stock Track | Phathom Pharmaceuticals Soars 5.79% Pre-market on Strong Q3 Earnings and Analyst Upgrade","media":"Stock Track","content":"<p>Phathom Pharmaceuticals (PHAT) saw its stock surge 5.79% in pre-market trading on Friday, following the release of its third-quarter earnings report for 2025 and a positive analyst update. The biopharmaceutical company's shares responded favorably to what appears to be strong financial results and an improved outlook from Wall Street.</p>\n\n<p>The company's Q3 earnings release, which came out late Thursday, seems to have impressed investors. While specific details were not provided, the report likely showcased significant growth and potentially better-than-expected performance for Phathom Pharmaceuticals. This positive financial data appears to be a key driver behind the stock's pre-market rally.</p>\n\n<p>Adding to the bullish sentiment, H.C. Wainwright raised its target price for Phathom Pharmaceuticals from $20 to $26, representing a substantial increase in their valuation of the company. Furthermore, HC Wainwright & Co. maintained its \"Buy\" rating on the stock, reinforcing confidence in Phathom's future prospects. These analyst actions suggest that Wall Street sees potential for further growth and value creation in Phathom Pharmaceuticals, likely contributing to the stock's early morning surge.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Phathom Pharmaceuticals Soars 5.79% Pre-market on Strong Q3 Earnings and Analyst Upgrade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Phathom Pharmaceuticals Soars 5.79% Pre-market on Strong Q3 Earnings and Analyst Upgrade\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-31 21:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Phathom Pharmaceuticals (PHAT) saw its stock surge 5.79% in pre-market trading on Friday, following the release of its third-quarter earnings report for 2025 and a positive analyst update. The biopharmaceutical company's shares responded favorably to what appears to be strong financial results and an improved outlook from Wall Street.</p>\n\n<p>The company's Q3 earnings release, which came out late Thursday, seems to have impressed investors. While specific details were not provided, the report likely showcased significant growth and potentially better-than-expected performance for Phathom Pharmaceuticals. This positive financial data appears to be a key driver behind the stock's pre-market rally.</p>\n\n<p>Adding to the bullish sentiment, H.C. Wainwright raised its target price for Phathom Pharmaceuticals from $20 to $26, representing a substantial increase in their valuation of the company. Furthermore, HC Wainwright & Co. maintained its \"Buy\" rating on the stock, reinforcing confidence in Phathom's future prospects. These analyst actions suggest that Wall Street sees potential for further growth and value creation in Phathom Pharmaceuticals, likely contributing to the stock's early morning surge.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PHAT","symbol_name":"Phathom Pharmaceuticals","start_time":0,"source_url":"","article_id":"1128129861","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128129861","pubTimestamp":1761917298,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Phathom Pharmaceuticals (PHAT) saw its stock surge 5.79% in pre-market trading on Friday, following the release of its third-quarter earnings report for 2025 and a positive analyst update. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PHAT":"Phathom Pharmaceuticals"},"translate_title":"个股追踪|Phathom Pharmaceuticals盘前大涨5.79%因Q3盈利强劲及分析师上调评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHAT":1},"content_text":"Phathom Pharmaceuticals (PHAT) saw its stock surge 5.79% in pre-market trading on Friday, following the release of its third-quarter earnings report for 2025 and a positive analyst update. The biopharmaceutical company's shares responded favorably to what appears to be strong financial results and an improved outlook from Wall Street.\nThe company's Q3 earnings release, which came out late Thursday, seems to have impressed investors. While specific details were not provided, the report likely showcased significant growth and potentially better-than-expected performance for Phathom Pharmaceuticals. This positive financial data appears to be a key driver behind the stock's pre-market rally.\nAdding to the bullish sentiment, H.C. Wainwright raised its target price for Phathom Pharmaceuticals from $20 to $26, representing a substantial increase in their valuation of the company. Furthermore, HC Wainwright & Co. maintained its \"Buy\" rating on the stock, reinforcing confidence in Phathom's future prospects. These analyst actions suggest that Wall Street sees potential for further growth and value creation in Phathom Pharmaceuticals, likely contributing to the stock's early morning surge.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}